Oxycodone

Trump nominates Makary to reform FDA, Weldon to lead CDC, and Nesheiwat as surgeon general, aligning with anti-vaccine advocate Kennedy. Makary criticizes overprescribing and industry influence, aiming to restore FDA's scientific integrity. Weldon, a pro-life Republican, and Nesheiwat, a Fox News contributor, face Senate confirmation.

President-elect Donald Trump nominates Dr. Marty Makary to lead the FDA, selecting a surgeon opposing vaccine mandates. Makary, a Johns Hopkins professor, aligns with anti-vaccine advocate Robert F. Kennedy Jr., Trump's nominee for HHS secretary. Trump also taps former Rep. Dave Weldon for CDC and Fox News contributor Janette Nesheiwat for surgeon general. Makary criticizes overprescribing and drug company influence, advocating for FDA reforms. Weldon, a pro-life Republican, and Nesheiwat, a Trump supporter, face Senate confirmation.

Trump nominates Dr. Marty Makary, a Johns Hopkins surgeon and healthcare critic, to lead the FDA. Makary is known for challenging vaccine mandates and advocating for systemic reforms, which could shift the agency's priorities towards stricter oversight and transparency, despite potential industry and bureaucratic resistance.

Protega Pharmaceuticals' Roxybond (oxycodone hydrochloride) 10 mg tablet, with SentryBond abuse-deterrent technology, is the first FDA-approved abuse-deterrent immediate-release oxycodone formulation, designed to reduce abuse via intranasal and intravenous routes. The approval addresses an unmet need for abuse-deterrent IR opioids, potentially reducing misuse and abuse while providing pain relief. Protega plans to launch Roxybond 10 mg by year-end, expanding its range of doses to enhance opioid therapy flexibility and safety.

FDA approves Protega Pharmaceuticals' ROXYBOND 10 mg oxycodone tablet with SentryBond technology, designed to deter abuse via intranasal and intravenous routes, marking a significant milestone in opioid abuse prevention.

FDA approves RoxyBond 10 mg, the first 10 mg abuse-deterrent immediate-release oxycodone, using SentryBond technology to resist physical manipulation, chemical extraction, and injection abuse.

FDA approves Protega's Roxybond, an abuse-deterrent, immediate-release 10 mg oxycodone for pain management, using SentryBond tech to reduce misuse via intranasal and IV routes. Despite over 2000 in vitro tests suggesting reduced abuse potential, Protega warns of life-threatening respiratory depression and contraindications. Roxybond aims to address the opioid epidemic, with 3-19% of pain medication users developing addiction.

Protega Pharmaceuticals received FDA approval for oxycodone hydrochloride (RoxyBond) 10 mg immediate-release tablets with SentryBond abuse-deterrent technology for managing severe pain. The tablets resist manipulation and chemical extraction, potentially extending the technology to other medications.

Protega Pharmaceuticals' Roxybond 10 mg tablets, approved by the FDA, use SentryBond technology to deter abuse through chemical extraction and physical manipulation, addressing severe pain management needs while reducing misuse and abuse.

Protega Pharmaceuticals announces FDA approval of ROXYBOND™, the first abuse-deterrent immediate-release opioid formulated with SentryBond™ technology, designed to reduce abuse via intranasal and intravenous routes. SentryBond technology aims to deter physical manipulation, chemical extraction, and injection misuse, with potential applications in other medications.